Cite
Cantor JO, Ma S, Liu X, et al. A 28-day clinical trial of aerosolized hyaluronan in alpha-1 antiprotease deficiency COPD using desmosine as a surrogate marker for drug efficacy. Respir Med. 2021;182:106402doi: 10.1016/j.rmed.2021.106402.
Cantor, J. O., Ma, S., Liu, X., Campos, M. A., Strange, C., Stocks, J. M., Devine, M. S., El Bayadi, S. G., Lipchik, R. J., Sandhaus, R. A., & Turino, G. M. (2021). A 28-day clinical trial of aerosolized hyaluronan in alpha-1 antiprotease deficiency COPD using desmosine as a surrogate marker for drug efficacy. Respiratory medicine, 182106402. https://doi.org/10.1016/j.rmed.2021.106402
Cantor, Jerome O, et al. "A 28-day clinical trial of aerosolized hyaluronan in alpha-1 antiprotease deficiency COPD using desmosine as a surrogate marker for drug efficacy." Respiratory medicine vol. 182 (2021): 106402. doi: https://doi.org/10.1016/j.rmed.2021.106402
Cantor JO, Ma S, Liu X, Campos MA, Strange C, Stocks JM, Devine MS, El Bayadi SG, Lipchik RJ, Sandhaus RA, Turino GM. A 28-day clinical trial of aerosolized hyaluronan in alpha-1 antiprotease deficiency COPD using desmosine as a surrogate marker for drug efficacy. Respir Med. 2021 Jun;182:106402. doi: 10.1016/j.rmed.2021.106402. Epub 2021 Apr 14. PMID: 33906126.
Copy
Download .nbib